GlassScriptPhysician profile
Gina M Liebl
NPI 1588224059
$3,890.52
in general payments reported to CMS, 2019-2025
21 companies · $896 in 2025
The $896 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $16.78 · 2023: $1,631 · 2024: $1,205 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.27 |
| Education | $428.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.83 | 2023-2025 | |
| Janssen Biotech, INC. | $595.71 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $430.02 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $352.41 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $323.30 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $313.94 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $176.94 | 2023-2025 | |
| Lilly USA, LLC | $162.60 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Pharmaceuticals, INC | $158.06 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $132.78 | 2023-2025 | Blu-U |
| Ucb, INC. | $126.22 | 2024-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Genzyme Corporation | $71.29 | 2023-2025 | |
| Incyte Corporation | $67.16 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $50.05 | 2023-2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $49.74 | 2023 | Idacio |
| Integra Lifesciences Corporation | $22.83 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.60 | 2024 | Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.61 | 2023 | Spevigo |
| Leo Pharma INC. | $17.27 | 2023 | Adbry |
| Organon LLC | $5.16 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Liebl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.